Chinese monkeypox vaccine gets green light for clinical trials - Chinadaily.com.cn
Sinopharm's domestic monkeypox vaccine candidate cleared for clinical trials, marking China's first. Developed by Shanghai Institute of Biological Products, it's a replication-deficient MVA vaccine, similar to Jynneos. Preclinical studies show good immune protection in nonhuman primates. No approved monkeypox vaccine exists in China yet.
Reference News
Company reports vaccine's safety, efficacy, and reliable production methods. Nonhuman primate models show good immune protection against monkeypox. No approved mpox vaccine in China; few globally approved in US, Canada, EU, Japan, Russia. WHO declared monkeypox in Africa a public health emergency in Aug 2023.
China’s top drug regulator clears Sinopharm’s mpox vaccine for clinical trials, potentially the country’s first experimental dose. The vaccine, developed by the Shanghai Institute of Biological Products, aims to control mpox infections. Currently, no approved mpox vaccine exists in China, while globally, a few are approved in the US, Canada, EU, Japan, and Russia.
China's first mpox vaccine, developed by Sinopharm, begins clinical trials with promising results for immunity protection. The vaccine aims to control mpox, classified as a Class B infectious disease in China, amid rising global cases. China has reported over 2,500 mpox cases, prompting enhanced screening measures for overseas arrivals.
China's top drug regulator approves Sinopharm's mpox vaccine for clinical trials, potentially marking the country's first experimental dose. The vaccine, developed by the Shanghai Institute of Biological Products, is based on the MVA strain, similar to the Jynneos vaccine approved by the FDA. Currently, no mpox vaccine is approved in China, while globally, a few are approved in the US, Canada, EU, Japan, and Russia. The World Health Organisation declared the mpox outbreak in Africa a public health emergency of international concern.
China's first domestically developed mpox vaccine, based on Modified Vaccinia Ankara (MVA), entered clinical trials. The vaccine, developed by the Shanghai Institute of Biological Products, has shown safety and efficacy in preclinical studies. Over 100,000 mpox cases and 220 deaths have been reported globally, prompting WHO to declare a Public Health Emergency of International Concern. China remains vigilant but sees low risk of rapid mpox spread.
China's top drug regulator has approved Sinopharm's mpox vaccine for clinical trials, potentially marking the country's first experimental dose. The vaccine, developed by the Shanghai Institute of Biological Products, is based on a strain called MVA and is similar to the Jynneos vaccine approved in the U.S. in 2019. The WHO has declared the mpox outbreak in Africa a public health emergency of international concern, with over 100,000 confirmed infections and 226 deaths globally. China reported its first domestic case in June last year, with 2,567 confirmed cases by the end of July.
Sinopharm's domestic monkeypox vaccine candidate cleared for clinical trials, marking China's first. Developed by Shanghai Institute of Biological Products, it's a replication-deficient MVA vaccine, similar to Jynneos. Preclinical studies show good immune protection in nonhuman primates. No approved monkeypox vaccine exists in China yet.
China's first independently developed mpox vaccine approved for human trials by National Medical Products Administration, potentially aiding in disease control. The vaccine, developed by Shanghai Institute of Biological Products, uses Modified Vaccinia Ankara strain technology similar to Bavarian Nordic's Jynneos. China has not yet approved any mpox vaccines for marketing, with only a few smallpox-adapted vaccines available in some countries.